Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.

Abstract

BACKGROUND AND STUDY AIMS:

Hepatitis C virus (HCV) prevalence inchronic kidney disease (CKD) patients is significantly higher than in the general population. This study evaluated the efficacy and safety of combined ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with renal impairment.

PATIENTS AND METHODS:

Our study included 829 patients with normal kidney functions (group 1) and 829 patients with CKD (group 2),which were subdivided into patients not requiring dialysis (group 2a) and those on hemodialysis (group2b). Patients received regimens of ombitasvir/paritaprevir/ritonavir with or without ribavirin or sofosbuvir/ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks. Clinical and laboratory assessment was done before treatment, and patients were followed up for12 weeks after treatment.

RESULTS:

The sustained virological response (SVR) at week 12 was significantly higher in group 1 than in the other three groups/subgroups, being 94.2% vs 90.2%, 90%, and 90.7%, respectively. The regimen with the highest SVR was ombitasvir/paritaprevir/ritonavir with ribavirin. The most common adverse event was anemia, which was more common in group 2.

CONCLUSION:

Ombitasvir/paritaprevir/ritonavir-based therapy in chronic HCV patients with CKD is highly effective, with minimal side effects despite ribavirin-induced anemia.

• Authors: Mohammad El-Sayed, Magdy Elserafy, Maissa El Raziky, Wafaa Elakel, Yasmin Saad, Tarek Fayad, Mohamed Korany, Mai Mehrez, Rabab Salama, Maged Mahrous, Ayman Zaki, Mohamed Hassany, Islam Ammar, Kadry Elsaeed, Yehia Elshazly, Wahid Doss
• Journal: Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (Arab J Gastroenterol) Vol. 24 Issue 1 Pg. 29-33 (Feb 2023) ISSN: 2090-2387 [Electronic] Egypt
• PMID: 36813580 (Publication Type: Journal Article)
• Copyright: Copyright © 2022. Published by Elsevier B.V.

Chemical References

• Ritonavir
• Ribavirin
• paritaprevir
• Antiviral Agents
• Valine
• Macrocyclic Compounds
• Anilides
• Carbamates

Topics

• Humans
• Ritonavir (adverse effects)
• Ribavirin (adverse effects)
• Antiviral Agents (adverse effects)
• Hepacivirus
• Valine (therapeutic use)
• Macrocyclic Compounds (therapeutic use, adverse effects)
• Drug Therapy, Combination
• Hepatitis C, Chronic (complications, drug therapy)
• Renal Insufficiency, Chronic (complications, chemically induced, drug therapy)
• Anilides (adverse effects)
• Carbamates (adverse effects)
• Genotype
• Treatment Outcome